Article

Changing Oncology Reimbursement Could Cut Drug Shortages, Lawmakers Told

Reforming oncology reimbursement is one method that could increase incentives to manufacturers and subsequently reduce drug shortages, according to testimony at a Senate Finance Committee hearing.

The hearing addressed causes of the recent drug shortages. About 30% of the drugs in short supply are oncology products.

Oncology drugs are reimbursed according to average sales price and an additional 6% markup that covers practice costs as a result of the Medicare Modernization Act in 2003, according to a perspective published last month in the New England Journal of Medicine. The authors said in the perspective that oncologists have incentive to use brand-name drugs that will provide a higher margin.

Read more: Changing oncology reimbursement could cut drug shortages, lawmakers told

Source: Modern Healthcare

Related Videos
Roberto Salgado, MD.
1 KOL is featured in this series.
1 expert is featured in this series.
5 experts are featured in this series
Keith Ferdinand, MD, professor of medicine, Gerald S. Berenson chair in preventative cardiology, Tulane University School of Medicine
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo